- Home
- TNON vs NLSP Comparison
TNON vs NLSP Comparison
Compare TNON & NLSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TNON
- NLSP
- Stock Information
- Founded
- TNON 2012
- NLSP 2015
- Country
- TNON United States
- NLSP Switzerland
- Employees
- TNON N/A
- NLSP N/A
- Industry
- TNON Medical Specialities
- NLSP Biotechnology: Pharmaceutical Preparations
- Sector
- TNON Health Care
- NLSP Health Care
- Exchange
- TNON Nasdaq
- NLSP Nasdaq
- Market Cap
- TNON 11.5M
- NLSP 12.4M
- IPO Year
- TNON 2022
- NLSP 2021
- Fundamental
- Price
- TNON $1.18
- NLSP $1.87
- Analyst Decision
- TNON Strong Buy
- NLSP
- Analyst Count
- TNON 2
- NLSP 0
- Target Price
- TNON $5.50
- NLSP N/A
- AVG Volume (30 Days)
- TNON 158.8K
- NLSP 943.2K
- Earning Date
- TNON 11-12-2025
- NLSP 10-06-2025
- Dividend Yield
- TNON N/A
- NLSP N/A
- EPS Growth
- TNON N/A
- NLSP N/A
- EPS
- TNON N/A
- NLSP N/A
- Revenue
- TNON $2,947,000.00
- NLSP N/A
- Revenue This Year
- TNON $43.52
- NLSP N/A
- Revenue Next Year
- TNON $82.14
- NLSP N/A
- P/E Ratio
- TNON N/A
- NLSP N/A
- Revenue Growth
- TNON N/A
- NLSP N/A
- 52 Week Low
- TNON $0.85
- NLSP $1.30
- 52 Week High
- TNON $5.85
- NLSP $5.64
- Technical
- Relative Strength Index (RSI)
- TNON 46.33
- NLSP 42.28
- Support Level
- TNON $1.15
- NLSP $1.81
- Resistance Level
- TNON $1.25
- NLSP $2.15
- Average True Range (ATR)
- TNON 0.04
- NLSP 0.19
- MACD
- TNON 0.00
- NLSP -0.02
- Stochastic Oscillator
- TNON 30.43
- NLSP 13.57
About TNON Tenon Medical Inc.
Tenon Medical Inc is a medical device company that has developed a novel, minimally invasive approach to the sacroiliac joint (the SI Joint) using a single, robust, titanium implant for the treatment of the common types of SI Joint disorders that cause lower back pain. The Company is focused on three commercial opportunities; Primary SI Joint procedures, Revision procedures of failed SI Joint implants, and SI Joint fusion adjunct to a spine fusion construct. The company derives the majority of its revenue from sales of The Catamaran System to a limited number of clinicians.
About NLSP NLS Pharmaceutics Ltd.
NLS Pharmaceutics Ltd a clinical-stage biopharmaceutical company focused on the discovery and development of inventive therapies for patients with rare and complex CNS disorders with unmet medical needs. Its compound, mazindol, a triple monoamine reuptake inhibitor and partial orexin receptor 2 agonist, in a proprietary ER formulation, is being developed for the treatment of narcolepsy, IH (follow-on indication), and potentially ADHD (back-up indication). Its lead products are Quilience, to treat narcolepsy and Nolazol, to treat ADHD.